MSLN Knockout OVCAR3 Cell Line

MSLN Knockout OVCAR3 Cell Line is an ovarian cancer OVCAR3 cell line in which human MSLN (Mesothelin) has been genetically removed using CRISPR/Cas9 genome editing. This cell line was generated by electroporation with the Cas9 enzyme (Streptococcus pyogenes) and sgRNA targeting human MSLN (Mesothelin). The cell line has been validated by NGS (next-generation sequencing) and flow cytometry. Mesothelin (MSLN) is a glycophosphatidylinositol (GPI)-linked cell surface protein that is produced as a ~70 kDa precursor protein and cleaved by Furin protease to generate the ~40 kDa mature form. MSLN is frequently overexpressed in mesothelioma, ovarian, pancreatic, and non-small cell lung (NSCLC) cancers, while its expression in normal tissues is restricted to the mesothelial lining. MSLN is a tumor-associated antigen and has been an attractive target for targeted immunotherapy approaches, including antibodies drug-conjugated (ADCs) and chimeric antigen receptor T cells (CAR-T Cells). The OVCAR3 cell line was isolated from a high-grade serous ovarian adenocarcinoma patient refractory to treatment with cisplatin. This cell line is highly tumorigenic and presents an abnormal karyotype. OVCAR3 cells are a widely used model of ovarian cancer, particularly for drug resistance studies and hormonal therapy.